GSGabriele Schackert

Gabriele Schackert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gabriele Schackert has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identification of Epigenetically Regulated Genes Distinguishing Intracranial from Extracranial Melanoma Metastases

    by Dana Westphal, Matthias Meinhardt, Konrad Grützmann, Lisa Schöne, Julian Steininger, Lena T. Neuhaus, Miriam Wiegel, Daniel Schrimpf, Daniela E. Aust, Evelin Schröck, et al.


  • Open Access

    A new approach for clinical translation of infrared spectroscopy: exploitation of the signature of glioblastoma for general brain tumor recognition

    by Gerald Steiner, Roberta Galli, Grit Preusse, Susanne Michen, Matthias Meinhardt, Achim Temme, Stephan B. Sobottka, Tareq A. Juratli, Edmund Koch, Gabriele Schackert, et al.

    Purpose: Infrared (IR) spectroscopy has the potential for tumor delineation in neurosurgery. Previous research showed that IR spectra of brain tumors are generally characterized by reduced lipid-related and increased protein-related bands. Therefore, we propose the exploitation of these common spectral changes for brain tumor recognition. Methods: Attenuated total reflection IR spectroscopy was performed on fresh specimens of 790 patients within minutes after resection. Using principal component analysis and linear discriminant analysis, a classification model was developed on a subset of glioblastoma (n = 135) and non-neoplastic brain (n = 27) specimens, and then applied to classify the IR spectra of several types of brain tumors. Results: The model correctly classified 82% (517/628) of specimens as “tumor” or “non-tumor”, respectively. While the sensitivity was limited for infiltrative glioma, this approach recognized GBM (86%), other types of primary brain tumors (92%) and brain metastases (92%) with high accuracy and all non-tumor samples were correctly identified. Conclusion: The concept of differentiation of brain tumors from non-tumor brain based on a common spectroscopic tumor signature will accelerate clinical translation of infrared spectroscopy and related technologies. The surgeon could use a single instrument to detect a variety of brain tumor types intraoperatively in future clinical settings. Our data suggests that this would be associated with some risk of missing infiltrative regions or tumors, but not with the risk of removing non-tumor brain.

  • Open Access

    Correlation of biomechanics and cancer cell phenotype by combined Brillouin and Raman spectroscopy of U87-MG glioblastoma cells

    by Jan Rix, Ortrud Uckermann, Katrin Kirsche, Gabriele Schackert, Edmund Koch, Matthias Kirsch, Roberta Galli

    The elucidation of biomechanics furthers understanding of brain tumor biology. Brillouin spectroscopy is a new optical method that addresses viscoelastic properties down to subcellular resolution in contact-free manner. Moreover, it can be combined with Raman spectroscopy to obtain co-localized biochemical information. Here, we applied co-registered Brillouin and Raman spectroscopy to U87-MG human glioblastoma cells in vitro. Using 2D and 3D cultures, we related biomechanical properties with local biochemical composition at subcellular level, as well as cell phenotype. Brillouin and Raman mapping of adherent cells showed that the nucleus and nucleoli are stiffer than the perinuclear region and the cytoplasm. The biomechanics of cell cytoplasm is affected by culturing conditions, i.e. cells grown as spheroids being stiffer than adherent cells. Inside the spheroids, the presence of lipid droplets as assessed by Raman spectroscopy reveals higher Brillouin shifts which is not related to local stiffness increase, but due to a higher refractive index combined with a lower mass density. This highlights the importance of locally defined biochemical reference data for a correct interpretation of the Brillouin shift of cells and tissue in future studies investigating the biomechanics of brain tumor models by Brillouin spectroscopy.

  • Brillouin confocal microscopy to determine biomechanical properties of SULEEI-treated bovine pericardium for application in cardiac surgery

    by Anett Jannasch, Jan Rix, Cindy Welzel, Gabriele Schackert, Matthias Kirsch, Ulla König, Edmund Koch, Klaus Matschke, Sems Malte Tugtekin, Claudia Dittfeld, et al.

    BACKGROUND: Heart valves are exposed to a highly dynamic environment and underlie high tensile and shear forces during opening and closing. Therefore, analysis of mechanical performance of novel heart valve bioprostheses materials, like SULEEI-treated bovine pericardium, is essential and usually carried out by uniaxial tensile tests. Nevertheless, major drawbacks are the unidirectional strain, which does not reflect the in vivo condition and the deformation of the sample material. An alternative approach for measurement of biomechanical properties is offered by Brillouin confocal microscopy (BCM), a novel, non-invasive and three-dimensional method based on the interaction of light with acoustic waves. OBJECTIVE: BCM is a powerful tool to determine viscoelastic tissue properties and is, for the first time, applied to characterize novel biological graft materials, such as SULEEI-treated bovine pericardium. Therefore, the method has to be validated as a non-invasive alternative to conventional uniaxial tensile tests. METHODS: Vibratome sections of SULEEI-treated bovine pericardium (decellularized, riboflavin/UV-cross-linked and low-energy electron irradiated) as well as native and GA-fixed controls (n = 3) were analyzed by BCM. In addition, uniaxial tensile tests were performed on equivalent tissue samples and Young’s modulus as well as length of toe region were analyzed from stress-strain diagrams. The structure of the extracellular matrix (ECM), especially collagen and elastin, was investigated by multiphoton microscopy (MPM). RESULTS: SULEEI-treated pericardium exhibited a significantly higher Brillouin shift and hence higher tissue stiffness in comparison to native and GA-fixed controls (native: 5.6±0.2 GHz; GA: 5.5±0.1 GHz; SULEEI: 6.3±0.1 GHz; n = 3, p < 0.0001). Similarly, a significantly higher Young’s modulus was detected in SULEEI-treated pericardia in comparison to native tissue (native: 30.0±10.4 MPa; GA: 31.8±10.7 MPa; SULEEI: 42.1±7.0 MPa; n = 3, p = 0.027). Native pericardia showed wavy and non-directional collagen fibers as well as thin, linear elastin fibers generating a loose matrix. The fibers of GA-fixed and SULEEI-treated pericardium were aligned in one direction, whereat the SULEEI-sample exhibited a much denser matrix. CONCLUSION: BCM is an innovative and non-invasive method to analyze elastic properties of novel pericardial graft materials with special mechanical requirements, like heart valve bioprostheses.


  • Open Access

    Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

    by Linda M. Liau, Keyoumars Ashkan, David D. Tran, Jian L. Campian, John E. Trusheim, Charles S. Cobbs, Jason A. Heth, Michael Salacz, Sarah Taylor, Stacy D. D’aNdre, et al.

    Following publication of the original article [1], the authors reported an error in the spelling of one of the author names. In this Correction the incorrect and correct author names are indicated and the author name has been updated in the original publication. The authors also reported an error in the Methods section of the original article. In this Correction the incorrect and correct versions of the affected sentence are indicated. The original article has not been updated with regards to the error in the Methods section.


  • TERT promoter mutations in progressive treatment-resistant meningiomas.

    by Tareq A. Juratli, Christian Thiede, Dietmar Krex, Priscilla Kaliopi Brastianos, Hiroaki Wakimoto, Gabriele Schackert, Matthias Kirsch, Daniel P. Cahill

    2047 Background: Recurrent meningiomas often undergo a grade-progression to become atypical or malignant upon recurrence. Detailed study of progressive meningioma has been hampered by the lack of available paired specimens. Here, we sequenced the TERT promoter (TERTp) in a large series of patients with treatment-resistant meningiomas at initial diagnosis as well as their sequential recurrences. Methods: We scored 77 meningiomas from 36 patients for TERTp mutations. All patients in this study developed recurrences during the median follow-up of 13.3 years (range 6.4 - 25.5 years) and underwent three surgeries on average (range 2-8). Additionally, we screened geographically distinct sites of all TERTp-mutant meningiomas to interrogate intratumoral heterogeneity. Results: TERTp mutations were detected in 18 tumor samples (18/77 = 23.3%) from 12 patients, but not in any of the matched blood sample DNAs, excluding germline mutations. Notably, the TERTp mutations were absent in the initial lower-grade tumor and were present in the subsequent recurrent tumors. Moreover, we observe emergent spatial heterogeneity in the form of mixed populations of recurrent tumor cells containing different mutation status of the TERT promoter gene in three cases. Patients with emergence of TERTp-mutant meningiomas had a significantly shorter overall survival than their TERTp wild-type counterparts, when measured from the time of initial diagnosis (2.4 vs 11.1 years, 95% CI 0.25-4.54 vs 9.3- 16.8 years p = 0.007). Conclusions: Our data confirm the high frequency of TERTp mutations and the emergence of TERT promoter mutation in recurrent progressive meningiomas, strongly indicating the presence of ongoing evolution impacting the natural history of these tumors. TERTp mutations are mostly associated with poor outcome. Finally, our study provides important insight into the complexity of tumor heterogeneity and has important implications for targeted therapy in treatment-resistant meningiomas.


  • Open Access

    Postoperative cerebellar mutism in adult patients with Lhermitte-Duclos disease

    by Ali Afshar-Oromieh, Heinz Linhart, Dino Podlesek, Wiebke Schrempf, Gabriele Schackert, Dietmar Krex

    Cerebellar mutism (CM) is a rare and severe form of speech and language impairment, mostly diagnosed in children and adolescents and rarely reported in adults. We here review the literature and summarize all anatomical structures related to the pathogenesis of this rare syndrome. We also report two illustrative cases of CM following surgical treatment of Lhermitte-Duclos disease (LDD; dysplastic gangliocytoma) in two adult patients. LDD is a rare benign cerebellar tumor. Surgical excision appears to be the only effective treatment. However, surgery is hampered by the difficulty to distinguish between tumor and healthy cerebellar tissue, which may result in extensive resection and cause neurological deficits such as CM. A review of the literature and our two cases suggest that lesions or functional impairment of paravermian structures including dentate nuclei, vermis, lateral hemispheres, and cerebellocortical pathways contribute to the development of CM. However, there is no single anatomical structure identified to be associated with CM. It is unknown whether some diseases such as LDD carry a higher risk of postoperative CM than others. As illustrated by our two cases, although there are no special means, optimal preoperative diagnosis might contribute to the prevention of this syndrome. Despite the severity, CM carries a favorable prognosis and generally resolves within a few months. To conclude, we review the clinical signs and particularly the pathophysiological observations and anatomical structures affected in the development of postoperative CM and contribute two cases illustrating the pathogenesis, prognosis, and possible prevention of this syndrome, to focus that CM might also occur in adults even in association with rare tumors.


  • Computer-based assessment of cognitive functions in brain tumor patients

    by Klaus Fliessbach, Sabine Rogowski, Christian Hoppe, Michael Sabel, Mathias Goeppert, Christoph Helmstaedter, Pasquale Calabrese, Gabriele Schackert, Joerg-Christian Tonn, Matthias Simon, et al.

    NeuroCogFX is a short yet comprehensive computer-based neuropsychological battery of tests developed to investigate neurological patients for cognitive dysfunction after potentially neurotoxic therapy. NeuroCogFX had been standardized in a group of 242 healthy controls (Fliessbach et al., Fortschr Neurol Psychiatr 74:643–650, 2006). The present study was conducted to assess the practicability, reliability, and validity of NeuroCogFX in brain tumor patients without active disease after tumor-directed therapy. To evaluate its validity, neuropsychological testing with NeuroCogFX was completed parallel to a battery of established neuropsychological tests in 54 patients with different types of brain tumors and without active disease for at least 6 months. Retest reliability was assessed in a different sample of 49 patients with gliomas. Results showed good practicability with a median test duration of 28 min (range 16–51 min). Most subtests showed medium-sized retest reliability in healthy controls and tumor patients, with the exception of the 2-back test and reaction time measures in tumor patients. Convergent validity was confirmed for the domains psychomotor speed, verbal memory, and verbal short-term memory. NeuroCogFX enables serial scientific neuropsychological assessment of brain tumor patients. It can be carried out within a short period of time by non-academic personnel and is therefore applicable to large cohorts, e.g., within clinical trials.


  • Integration of Intraoperative 3D-Ultrasound in a Commercial Navigation System

    by O. Sergeeva, F. Uhlemann, G. Schackert, C. Hergeth, U. Morgenstern, R. Steinmeier

    Study Aims: The purpose of this study was the integration of three-dimensional ultrasound data into a neuronavigation system, in order to allow a guided intraoperative resection control during neurosurgical interventions. Material und Methods: A system for iterative neuronavigation based on 3D-ultrasound (US) has been developed. The main components of the system are the ultrasound device Voluson 730 (GE Healthcare) with a 5 - 9 MHz probe, the navigation system VectorVision2® (BrainLAB AG) and a standard PC with Windows XP. The ultrasound data are transferred via DICOM from the ultrasound device to an external computer, where they are processed with a C++ program for representation in the neuronavigation coordinate system. The data transfer between the navigation system and the external computer is performed via the VVLink interface from BrainLAB. The feasibility test of the system was performed with an ultrasound phantom RMI 403GS (Gammex-RMI GmbH). Results: The error of homologous points mapping from US datasets to a CT dataset in the neuronavigation system was determined to be 1.9 ± 0.97 mm. The maximum time required to technically integrate the ultrasound data into the navigation system was 1.5 min. Conclusions: The developed system allows 3D-ultrasound based navigation to be carried out with a commercially available navigation system. The functionality of this system has been proven by technical tests. Recording and integration of the ultrasound data can be repeated at any time during surgery and can be used to update anatomical data and consequently for resection control. Another application is the intraoperative adaptation of preoperative datasets (MRI or CT) in order to compensate for “brain shift” during neurosurgical operations. Ziele der Studie: Das Ziel war die Integration dreidimensionaler Ultraschalldaten in ein kommerzielles Navigationssystem, um eine navigierte intraoperative Resektionskontrolle bei neurochirurgischen Eingriffen zu ermöglichen. Material und Methoden: Das System für die intraoperative 3D-Ultraschallnavigation wurde entwickelt. Die Hauptkomponenten des Systems sind das Ultraschallgerät Voluson 730 von GE Healthcare (ehem. Kretztechnik AG) mit der 5 - 9-MHz-Sonde, Navigationssystem VectorVision2® von der Fa. BrainLAB AG und ein Standardrechner mit Windows XP-System. Die Ultraschalldaten werden per DICOM vom Ultraschallgerät an einen externen Rechner übertragen und dort mit einem C++-Programm für die Darstellung im Navigationskoordinatensystem transformiert. Die Datenübertragung zwischen dem Navigationssystem und dem Rechner erfolgt über die VVLink-Schnittstelle von der Firma BrainLAB. Der Test der Systemfunktionalität wurde mit einem US-Phantom RMI 403GS der Firma Gammex-RMI GmbH durchgeführt. Ergebnisse: Die für das System berechnete Genauigkeit der Abbildung der entsprechenden Datenpunkte vom US-Datensatz auf den CT-Datensatz im Navigationssystem beträgt 1,9 ± 0,97 mm. Die technisch notwendige Zeit für die Integration von 3D-Ultraschalldaten in die Navigation liegt innerhalb von 1,5 min. Schlussfolgerungen: Das entwickelte System ermöglicht einen navigierten Einsatz der intraoperativen 3D-US-Daten in einem kommerziellen Neuronavigationssystem. Der Test hat die Funktionalität des Systems bestätigt. Die US-Untersuchung ist mehrfach wiederholbar und kann für die Aktualisierung der anatomischen Daten und für die Resektionskontrolle benutzt werden. Eine weitere mögliche Systemanwendung ist die intraoperative Adaptation präoperativer Datensätze (CT oder MRT) für die Verfolgung von “brain shift” bei neurochirurgischen Operationen.


  • The Transaxillary Approach in the Treatment of Thoracic Outlet Syndrome: A Neurosurgical Appraisal

    by K. G. Krishnan, Th. Pinzer, G. Schackert

    Object: Different surgical approaches are available for the treatment of thoracic outlet syndrome (TOS). Our aim is to describe the transaxillary approach from a neurosurgical perspective, and to present the results in 15 patients. Methods and Results: Fifteen patients (6 m and 9 f; mean age 44 yrs) were treated for neurogenic TOS. Four patients (26.7 %) demonstrated a cervical rib. The rest did not show a diagnosable bony anomaly (73.3 %). Provocative tests were neurologically positive in all patients (100 %); 4 patients additionally demonstrated vascular symptoms (26.7 %). Six patients demonstrated ulnar nerve F-wave latency (40 %). The transaxillary approach was used in all patients. In three patients with cervical ribs (20 %), an additional ventral approach was utilized. 14 patients remain symptom-free at a mean follow-up period of 24 months (93.4 %). One complained of pain recurrence at nine months after surgery and was treated conservatively (2œ yrs). One patient developed pneumothorax after surgery (6.7 %). Four patients reported on numbness of the lateral thoracic wall, due to stretch injury of the intercostobrachial nerve that lies along the approach corridor (26.7 %). Conclusion: The transaxillary approach is one of several described surgical options for the treatment of TOS. It lies along a natural corridor and is non-muscle splitting. Although it requires a deep surgical corridor, the transaxillary approach allows definitive treatment of both bony and soft-tissue components causing TOS, provided the anatomical boundaries are recognized and respected. A persistent cervical rib, however, calls for an additional ventral approach. The complications are minimal and the results are predominantly acceptable. Ziel: In diesem Artikel beschreiben wir den transaxillären Zugang bei der operativen Behandlung des Thoracic-outlet-Syndroms (TOS) von einer neurochirurgisch-anatomischen Perspektive und stellen unsere Ergebnisse bei 15 Patienten vor. Methode und Ergebnisse: 6 Männer und 9 Frauen wurden wegen neurogenem oder kombiniertem TOS behandelt. 4 Patienten (26,7 %) zeigten eine Halsrippe. Die übrigen Patienten wiesen keine radiologisch auffälligen knöchernen Anomalien auf (73,3 %). Provokationsteste waren bei allen Patienten neurologisch positiv (100 %); 4 Patienten zeigten zusätzlich vaskuläre Symptome (26,7 %). Bei 6 Patienten konnte eine F-Wellenlatenz des N. ulnaris nachgewiesen werden (40 %). Der transaxilläre Zugang wurde bei allen Patienten gewählt. Bei vier Patienten mit Halsrippe (26,7 %) wurde zusätzlich ein ventraler Zugang durchgeführt. Bei einem Patienten stellten wir postoperativ einen Pneumothorax fest (6,7 %). 14 Patienten (93,3 %) waren frei von TOS-Symptomen bei einem durchschnittlichen Follow-up von 24 Monaten. Eine Patientin klagte über ein erneutes TOS neun Monate nach der Operation. 4 Patienten (26,7 %) berichteten über Hypästhesien im Bereich der lateralen Thoraxwand. Schlussfolgerung: Der transaxilläre Zugang folgt einem natürlich vorhandenen Korridor, und es ist nicht notwendig, Muskulatur zu spalten. Außerdem muss am Plexus brachialis und den subklavikulären Gefäßen wenig manipuliert werden. Deshalb ist dieser Weg schonend und wenig invasiv. Obwohl das Operationsfeld in großer Tiefe liegt, erlaubt er die definitive und sichere Behandlung eines TOS unter Berücksichtigung und Respektierung der anatomischen Grenzen. Bei persistenten Halsrippen ist jedoch ein zusätzlicher ventraler Zugang notwendig. Die Komplikationen sind gering und die Ergebnisse gut.